Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy : A randomised, double-blind, placebo-controlled trial. / Wegeberg, Anne Marie Langmach; Hansen, Christian Stevns; Farmer, Adam D.; Karmisholt, Jesper Scott; Drewes, Asbjorn M.; Jakobsen, Poul Erik; Brock, Birgitte; Brock, Christina.

I: United European Gastroenterology Journal, Bind 8, Nr. 6, 07.2020, s. 695-704.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Wegeberg, Anne Marie Langmach ; Hansen, Christian Stevns ; Farmer, Adam D. ; Karmisholt, Jesper Scott ; Drewes, Asbjorn M. ; Jakobsen, Poul Erik ; Brock, Birgitte ; Brock, Christina. / Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy : A randomised, double-blind, placebo-controlled trial. I: United European Gastroenterology Journal. 2020 ; Bind 8, Nr. 6. s. 695-704.

Bibtex

@article{b5e1d455b3a140c8924fa9f18a7180de,
title = "Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial",
abstract = "Background: Glucagon-like peptide-1 receptor agonists, such as liraglutide, reduce hyperglycaemia and induce weight loss and are used as a treatment in diabetes. However, common adverse effects include nausea, loss of appetite and prolonged gastric emptying. It is not known whether these changes are centrally generated or if liraglutide alters the enteric motility. Objective: To investigate the effects of liraglutide on gastrointestinal function and symptoms. Methods: A total of 48 adults with type 1 diabetes and confirmed distal symmetric polyneuropathy were randomised to receive liraglutide 1.8 mg/day or placebo for 26 weeks. Regional transit times and motility indexes were assessed with a wireless motility capsule, whereas symptoms were evaluated using the validated gastroparesis cardinal symptom index. Results: Liraglutide treatment reduced large bowel transit time (31.7%, p = 0.04) and decreased motility index (6.1%, p = 0.04) compared to placebo, whereas the groups did not differ in gastric emptying or small-bowel transit times. Liraglutide increased postprandial fullness with 29% (p = 0.01). Increased small bowel transit time was associated with decreased bloating (p = 0.008). Conclusion: Liraglutide accelerates large bowel transit and decreases motility index, which may indicate better coordination of propulsive motility. This potentially improves the function of the enteric nervous system, leading to normalised colonic function and positive effects in type 1 diabetes.",
keywords = "Diabetes mellitus type 1, digestive signs and symptoms, gastrointestinal motility, gastrointestinal transit, liraglutide, polyneuropathies",
author = "Wegeberg, {Anne Marie Langmach} and Hansen, {Christian Stevns} and Farmer, {Adam D.} and Karmisholt, {Jesper Scott} and Drewes, {Asbjorn M.} and Jakobsen, {Poul Erik} and Birgitte Brock and Christina Brock",
year = "2020",
month = jul,
doi = "10.1177/2050640620925968",
language = "English",
volume = "8",
pages = "695--704",
journal = "United European Gastroenterology Journal",
issn = "2050-6406",
publisher = "SAGE Publications Ltd",
number = "6",

}

RIS

TY - JOUR

T1 - Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy

T2 - A randomised, double-blind, placebo-controlled trial

AU - Wegeberg, Anne Marie Langmach

AU - Hansen, Christian Stevns

AU - Farmer, Adam D.

AU - Karmisholt, Jesper Scott

AU - Drewes, Asbjorn M.

AU - Jakobsen, Poul Erik

AU - Brock, Birgitte

AU - Brock, Christina

PY - 2020/7

Y1 - 2020/7

N2 - Background: Glucagon-like peptide-1 receptor agonists, such as liraglutide, reduce hyperglycaemia and induce weight loss and are used as a treatment in diabetes. However, common adverse effects include nausea, loss of appetite and prolonged gastric emptying. It is not known whether these changes are centrally generated or if liraglutide alters the enteric motility. Objective: To investigate the effects of liraglutide on gastrointestinal function and symptoms. Methods: A total of 48 adults with type 1 diabetes and confirmed distal symmetric polyneuropathy were randomised to receive liraglutide 1.8 mg/day or placebo for 26 weeks. Regional transit times and motility indexes were assessed with a wireless motility capsule, whereas symptoms were evaluated using the validated gastroparesis cardinal symptom index. Results: Liraglutide treatment reduced large bowel transit time (31.7%, p = 0.04) and decreased motility index (6.1%, p = 0.04) compared to placebo, whereas the groups did not differ in gastric emptying or small-bowel transit times. Liraglutide increased postprandial fullness with 29% (p = 0.01). Increased small bowel transit time was associated with decreased bloating (p = 0.008). Conclusion: Liraglutide accelerates large bowel transit and decreases motility index, which may indicate better coordination of propulsive motility. This potentially improves the function of the enteric nervous system, leading to normalised colonic function and positive effects in type 1 diabetes.

AB - Background: Glucagon-like peptide-1 receptor agonists, such as liraglutide, reduce hyperglycaemia and induce weight loss and are used as a treatment in diabetes. However, common adverse effects include nausea, loss of appetite and prolonged gastric emptying. It is not known whether these changes are centrally generated or if liraglutide alters the enteric motility. Objective: To investigate the effects of liraglutide on gastrointestinal function and symptoms. Methods: A total of 48 adults with type 1 diabetes and confirmed distal symmetric polyneuropathy were randomised to receive liraglutide 1.8 mg/day or placebo for 26 weeks. Regional transit times and motility indexes were assessed with a wireless motility capsule, whereas symptoms were evaluated using the validated gastroparesis cardinal symptom index. Results: Liraglutide treatment reduced large bowel transit time (31.7%, p = 0.04) and decreased motility index (6.1%, p = 0.04) compared to placebo, whereas the groups did not differ in gastric emptying or small-bowel transit times. Liraglutide increased postprandial fullness with 29% (p = 0.01). Increased small bowel transit time was associated with decreased bloating (p = 0.008). Conclusion: Liraglutide accelerates large bowel transit and decreases motility index, which may indicate better coordination of propulsive motility. This potentially improves the function of the enteric nervous system, leading to normalised colonic function and positive effects in type 1 diabetes.

KW - Diabetes mellitus type 1

KW - digestive signs and symptoms

KW - gastrointestinal motility

KW - gastrointestinal transit

KW - liraglutide

KW - polyneuropathies

UR - http://www.scopus.com/inward/record.url?scp=85084546958&partnerID=8YFLogxK

U2 - 10.1177/2050640620925968

DO - 10.1177/2050640620925968

M3 - Journal article

C2 - 32390563

AN - SCOPUS:85084546958

VL - 8

SP - 695

EP - 704

JO - United European Gastroenterology Journal

JF - United European Gastroenterology Journal

SN - 2050-6406

IS - 6

ER -